![]() ![]() “We’re pleased to collaborate with Regeneron as we expand evaluation of vidutolimod as a potent stimulator of innate immune activity to patients with life-threatening non-melanoma skin cancers such as CSCC and MCC,” said Barry Labinger, president and chief executive officer of Checkmate. ![]() Checkmate will be the sponsor of the clinical trial, and Regeneron will supply cemiplimab. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi.Ĭheckmate and Regeneron will collaborate on a multi-indication, phase 2, proof-of-concept clinical trial of vidutolimod in combination with cemiplimab in the following patient cohorts: (a) PD-1 treatment-naïve subjects with cutaneous squamous cell carcinoma (CSCC), (b) subjects with cutaneous squamous cell carcinoma (CSCC) that is refractory to PD-1 blockade, and (c) subjects with Merkel cell carcinoma (MCC) that is refractory to PD-1 blockade. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Click hereĬheckmate Pharma inks clinical agreement with Regeneron to evaluate vidutolimod in combo with LibtayoĬheckmate Pharmaceuticals, a clinical stage biopharmaceutical company, announced the development programme expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals. You can get e-magazine links on WhatsApp. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |